~~<i id='7675CBA650'><strike id='7675CBA650'><tt id='7675CBA650'><pre id='7675CBA650'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：explore 2025-09-28 01:09:29 Page View：512

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Why Talkspace is targeting Medicare, a tricky market
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wikipedia

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Adults seen as increasingly susceptible to measles

MikeReddyforSTATSimonMatthewsmadethreetripsthisspringtotheemergencyroomofhislocalhospitalinEastbourn

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Micronoma's microbiome cancer diagnostic approach under fire

Amedicalillustrationofdrug-resistant,Streptococcuspneumoniaebacteria.AntibioticResistanceCoordinatio